Chronic Cluster Headache with Daily Attacks When Verapamil Has Not Achieved Adequate Prevention
This protocol covers chronic cluster headache (ICHD-3 3.1.2) in patients whose daily attacks have not been adequately controlled by verapamil — specifically when that first-choice preventive agent failed to reach the target response within its expected efficacy window.
Chronic cluster headache (ICHD-3 3.1.2) is a less common presentation, accounting for under 20% of cluster headache cases. It is defined by attacks occurring on a daily basis for at least one year, with any symptom-free periods lasting fewer than 3 months.
The prior preventive step in this patient involved verapamil. The goal of that line — at least a 50% reduction in attack frequency, with efficacy expected after 2–3 weeks — was not met. This protocol defines the recommended next step when verapamil is inefficacious or cannot be continued.
The protocol specifies an oral preventive agent indicated specifically when verapamil is inefficacious or contraindicated, alongside several alternative oral options. The primary clinical goal is a reduction in attack frequency, with the main agent's efficacy expected to be apparent relatively quickly.
References
DOI: 10.1111/ene.15956
In patients suffering from the less common chronic presentation (<20% of cluster headaches, ICHD-3 3.1.2), attacks often occur on a daily basis; if symptom-free periods are experienced, these last <3 months, for at least 1 year.
Lithium is a drug of second choice if verapamil is inefficacious or contraindicated.
Clinical efficacy is reached within 1 week.
View source ↗